Matthew Hewston
Sleep Medicine · Cedar Knolls, NJNPI 1275929135
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 133 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 24.4% of the total. 2025 is the largest year on record at $851, more than ten times the $27 reported in 2019.
Across 133 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$533
- GSK$532
- Axsome Therapeutics, Inc.$173
- Avadel CNS Pharmaceuticals, LLC$152
- Sanofi$96
- Regeneron Healthcare Solutions, Inc.$94
- plus $608 from 21 others
What the payments were for
- Food & beverage$2,188100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 30 | $533 |
| GSK | 39 | $532 |
| Axsome Therapeutics, Inc. | 11 | $173 |
| Avadel CNS Pharmaceuticals, LLC | 8 | $152 |
| Sanofi | 5 | $96 |
| Regeneron Healthcare Solutions, Inc. | 6 | $94 |
| Mylan Specialty L.p. | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Boehringer Ingelheim | 3 | $49 |
| Merck | 2 | $45 |
| Electromed, Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $37 |
| Harmony Biosciences LLC | 2 | $34 |
| Verona Pharma, Inc. | 2 | $33 |
| AbbVie | 2 | $32 |
| CSL Behring | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Insmed, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
How this compares
$2,188 in reported general payments places this provider in the 65th percentile of 40 sleep medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 12 | $158,821 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 196 | $147,729 |
| Breo ElliptaFluticasone/Vilanterol | 78 | $48,984 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $34,586 |
| Spiriva RespimatTiotropium Bromide | 26 | $18,398 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $17,274 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 19 | $11,635 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $10,499 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 78 | $8,549 |
| Arnuity ElliptaFluticasone Furoate | 36 | $7,823 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $7,581 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 233 | $7,380 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $6,417 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,848 |
| Armodafinil | 38 | $4,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $532 | $229,391367 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $49 | $188,85357 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $533 | $39,43370 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 40 sleep medicine providers in New Jersey.
Other sleep medicine in Cedar Knolls
- Matthew EpsteinCedar Knolls$716
- Prashant PatelBridgewater$20K
- Nehal MehtaBridgewater$19K
- Federico CerroneSummit$13K
- Thanuja HamiltonMount Laurel$9K
- Jimmy HannaNewark$7K
- Tanuj BhatnagarJersey City$7K
- Bankim ShahBoonton$7K
- Kalpeshkumar PatelOld Bridge$5K
- David OczosNeptune$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.